oxaliplatin

P2, N=84, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting

P2, N=110, Recruiting, Qilu Hospital of Shandong University | Not yet recruiting --> Recruiting

P1, N=50, Not yet recruiting, Hoffmann-La Roche | Trial completion date: Jan 2030 --> Sep 2029

Early dynamics of ctDNA during first-line oxaliplatin-based chemotherapy hold prognostic value, supporting the idea of prospectively validating a ctDNA-RECIST framework in the early care pathway of mCRC patients.

P2, N=50, Recruiting, Huashan Hospital | Trial primary completion date: Dec 2024 --> Jun 2025

The two cases suggest that an alternating chemotherapy regimen of oxaliplatin and irinotecan, combined with capecitabine and bevacizumab is effective in the treatment of MSS, BRAF V600E-mutated stage IV metastatic CRC. The progression-free survival was significantly prolonged (both exceeding 20 months) compared to the first-line standard chemotherapy regimen for this disease. With a good balance between toxicity and efficacy, this alternating chemotherapy regimen can be considered as a potential first-line option for microsatellite-stable metastatic colon cancer.

Our results support the concept that eribulin's cytotoxic effects are associated with ICD. These findings provide impetus for investigating how eribulin-induced ICD may contribute to the larger spectrum of phenotypic and immunological effects by which eribulin exerts antitumor therapeutic benefits.

A 72-year-old Japanese male patient with primary duodenal cancer with distal lymph node metastases received chemotherapy with S-1, an oral pyrimidine fluoride-derived agent, and oxaliplatin after gastrojejunal bypass, which resulted in tumor shrinkage; however, peritoneal dissemination developed. Despite the administration of a second-line chemotherapy regimen comprising irinotecan, peritoneal dissemination, malignant ascites, and cachexia continued to progress, ultimately resulting in the failure of chemotherapy...He has continued this treatment every few months as maintenance therapy and has been free of relapse for 54 months. This case suggests a possible beneficial effect of adoptive cell therapy with WT1/MUC1-DC and CAT for peritoneal dissemination and malignant ascites in duodenal cancer.

STEAP3 was significantly associated with CC progression mediated via the JAK/STAT3 signaling pathway and may serve as an effective therapeutic target.

The patient underwent six cycles of chemotherapy with FOLFOX (oxaliplatin in combination with 5-fluorouracil and leucovorin), and radiofrequency ablation (RFA) was applied to the lesion in segment VI, resulting in a favorable response in imaging control. In addition to the dissection and section of the middle and left hepatic vein included in the surgical specimen. The patient experienced a rapid postoperative recovery with good liver function, an early hospital discharge, and a quick return to work, highlighting the clear advantages of laparoscopic surgery.

Moreover, elevated COL8A1 promotes EMT and contributes to CRC oxaliplatin resistance, which can be mitigated by ITGB1 knockdown or AKT inhibitor. Collectively, these results highlight the crucial role of THBS2 + CAFs in promoting oxaliplatin resistance of CRC by activating EMT and provide a rationale for a novel strategy to overcome oxaliplatin resistance in CRC.

P2, N=141, Not yet recruiting, Fudan University

P3, N=340, Terminated, Alliance for Clinical Trials in Oncology | Unknown status --> Terminated

P2, N=44, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

P3, N=358, Active, not recruiting, Kyung Hee University Hospital at Gangdong | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jun 2026

While AOH generally suppressed a drug-induced activation and increased anti-inflammatory IL10 levels, DON potentiated activation and pro-inflammatory markers, such as CXCL8 and TNF in immune cells. In conclusion, AOH and DON have the potential to alter the immunological effects of anticancer therapies, which should be considered during therapy as well as in their future risk assessment.

The MOUNTAINEER-03 phase III trial is designed to investigate the efficacy and safety of first-line tucatinib in combination with trastuzumab and modified FOLFOX6 (mFOLFOX6) versus standard of care (mFOLFOX6 plus bevacizumab or cetuximab) in patients with untreated HER2+, RAS WT locally advanced unresectable or mCRC...Key secondary endpoints are overall survival and confirmed objective response rate (according to RECIST v1.1 per BICR). Safety assessments will include surveillance and recording of adverse events, physical examination findings, vital signs, cardiac assessments, Eastern Cooperative Oncology Group performance status, concomitant medications, and laboratory tests.Clinical trial registration: NCT05253651 (ClinicalTrials.gov).

P3, N=918, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jul 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> May 2025

P3, N=359, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed

P2, N=54, Terminated, Centre Hospitalier Universitaire de Besancon | N=177 --> 54 | Trial completion date: Dec 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2024; enrollment too slow

To solve this, we have developed dextran-based TAM targeting activator conjugate (D-TAC) technology which successfully uses tumor-associated macrophages (TAMs) to deliver the TLR7 agonist DSP-0509...In this study, we compared the anti-tumor effects of EIK1001 and 5DEX-0509R, and analyzed its unique immune reaction against tumors to evaluate whether 5DEX-0509R is suitable for further clinical study...We also found that 5DEX-0509R synergistically suppresses tumors with oxaliplatin by changing M2 macrophages that cause oxaliplatin to become resistant to antitumor M1 macrophages. In addition, 5DEX-0509R caused a rapid but not sustained cytokine elevation in both rats and dogs. We believe 5DEX-0509R is worth pursuing for clinical trials.

The efficacy of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin (OXA) and 5-fluorouracil (5-Fu) for treating advanced perihilar cholangiocarcinoma (pCCA) has been demonstrated, yet the survival benefits of HAIC for pCCA patients vary. Mechanistic investigations revealed secreted protein acidic and rich in cysteine (SPARC) as the direct target of miR-532-3p. Our study reveals that bile miR-532-3p, miR-1250-5p, and miR-4772-5p may serve as survival biomarkers in advanced pCCA patients after HAIC and that bile miR-532-3p promotes resistance to HAIC with OXA and 5-Fu via negatively regulating SPARC expression.

Drug susceptibility assays demonstrated that DPC-X3 resisted paclitaxel, oxaliplatin, 5-fluorouracil(5-FU), and gemcitabine. The Ki-67 proliferation index was determined to be approximately 40%. DPC-X3 presents a valuable experimental platform for elucidating the pathogenesis of intestinal-type AC and can serve as a driver for drug development efforts.

P1/2, N=186, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Jan 2026

P2, N=60, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting

P2/3, N=348, Active, not recruiting, Universität des Saarlandes | Trial completion date: Nov 2024 --> Dec 2025

P=N/A, N=196, Recruiting, The First Affiliated Hospital of Henan University of Science and Technology | Trial completion date: Jun 2021 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Dec 2024

P1/2, N=57, Not yet recruiting, West China Hospital

P1, N=21, Active, not recruiting, Bexion Pharmaceuticals, Inc. | Trial primary completion date: Sep 2024 --> Dec 2024

P=N/A, N=30, Not yet recruiting, French Society of Digestive Endoscopy

P2, N=36, Recruiting, West China Hospital

The TRG-based risk model could predict HCC patient prognosis and closely linked to tumor immune environment, which could offer new possibilities for clinical treatment.

P1, N=188, Recruiting, Amgen | Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: May 2026 --> Feb 2027

P2, N=30, Not yet recruiting, Peking University

P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P3, N=508, Recruiting, Fudan University | N=386 --> 508 | Trial completion date: Dec 2026 --> Sep 2027 | Trial primary completion date: Dec 2023 --> Mar 2025

P1/2, N=10, Not yet recruiting, Zhejiang Cancer Hospital

P1, N=52, Active, not recruiting, University Hospital, Grenoble | Recruiting --> Active, not recruiting

P1/2, N=480, Recruiting, Parabilis Medicines, Inc. | N=245 --> 480

P1/2, N=21, Not yet recruiting, University of Kansas Medical Center

P2, N=78, Recruiting, Sun Yat-sen University

P1/2, N=50, Active, not recruiting, Anup Kasi | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025